Business
China's Licensing Trends Shaping Global Drug Development Analysis Report 2025: Parent Companies Benefitted from Upfront Payments for R&D, Gaining Equity in Novel Chinese Therapeutics
China's biotech sector offers robust market opportunities driven by accelerated regulatory reforms, leading to a 21.7% CAGR in licensing deals. Key areas include oncology, immunology, and metabolic disorders, with significant activity in mAbs and small molecules. Notable is AstraZeneca's active involvement and the gains from upfront R&D payments.Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "China's Licensing Trends Shaping Global Drug Development" report has been added to ResearchAndMarkets.com
About this update from Astrazeneca Plc
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"China's biotech sector offers robust market opportunities driven by accelerated regulatory reforms, leading to a 21.7% CAGR in licensing deals. Key areas include oncology, immunology, and metabolic disorders, with significant activity in mAbs and small molecules. Notable is AstraZeneca's active involvement and the gains from upfront R&D payments.","length":360,"tagName":"p"},{"type":"text","content":"Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "China's Licensing Trends Shaping Global Drug Development" report has been added to ResearchAndMarkets.com's offering.Over the past five years, China's biotech sector's out-licensing deals have increased significantly. Between 2020 and 2024, the compound annual growth rate (CAGR) was approximately 21.7% for licensing agreements, which is a significant increase highlighting the strength of innovative drugs coming from China. This can be attributed to accelerated regulatory reforms, resulting in streamlined drug approvals and extended market exclusivity.Oncology accounted for 59% of these deals and made up 52% of the total deal value during this time period. Other therapy areas such as immunology and metabolic disorders have also had interest, accounting for 13% and 8% of deal activity, respectively. Out-licensing deals associated with mAbs had a total of 46 deals accounting for 36% between 2020-25 with a deal value of $45 billion. Small molecules followed with 32 deals accounting for 25%, with a deal value of $42 billion.Antibody-drug conjugates (ADCs) had fewer deals than mAbs and small molecules with a total of 31 deals (24%) and accounted for a deal value of $40 billon over the 5-year period. AstraZeneca led big pharma with the most out-licensing deals between 2020 and 2025 YTD, with nine deals valued at approximately $20 billion. Activity in 2...